Covishield and Covaxin
Image Credit: Business Standard
Covishield and Covaxin can now be Available for Sale in the Market
The Drugs Controller General of India (DCGI) has approved the adult population's access to the anti-Covid-19 vaccinations Covishield and Covaxin. This information came from an official source. According to sources, the vaccination will not be sold in medical stores. Hospitals and clinics can purchase vaccines, but they must furnish DCGI with vaccination data every six months.
Setting price caps for vaccines to make them more affordable
Sources indicated a day earlier on Wednesday that the cost of both vaccines would likely be regulated at Rs 275 per dosage plus a Rs 150 service charge. The National Pharmaceutical Pricing Authority (NPPA) has been asked to begin working on setting price caps for vaccines to make them more affordable.
Covishield and Covaxin
A single dose of Covishield costs Rs 780 in private institutions
Covaccine costs Rs 1,200 per dosage so far, while a single dose of Covishield costs Rs 780 in private institutions. A service charge of Rs.150 is also included in the prices. Both vaccinations are currently only approved for emergency usage in the country.
Covishield and Covaccine for use among the adult population
The Central Drugs Standard Control Organization's (CDSCO) Subject Expert Committee on Covid-19 recently approved the normal launch of the anti-Covid vaccinations Covishield and Covaccine for use among the adult population, subject to specific criteria. was suggested.
Covishield and Covaxin
Regular approval was given for vaccine few weeks ago
On October 25, Prakash Kumar Singh, Director (Government and Regulatory Affairs), Serum Institute of India, applied to the Drug Controller General of India for permission to commercialize the Covishield vaccine. V Krishna Mohan, Bharat Biotech's full-time director, filed detailed information on chemistry, manufacturing, and control, as well as clinical data, requesting regular approval for the vaccine a few weeks ago. On January 3 of last year, Covaccine and Covishield received Emergency Use Approval (EUA).